Key considerations for characterizing LNPs
Key considerations for LNP development, including structure and formulation. We explore analytics, physicochemical properties and quality attributes. Register now >>
We've got a fantastic selection of events coming in 2024 to support your pharmaceutical journeys!
From LNPs to nanoparticles, from data to processes, we'll be exploring a range of insightful topics, with an opportunity to ask your specific questions at each event.
Want to know more?
Take a look at the summary information below and register for free for any sessions in our webinar series - and keep an eye out for the recordings afterwards too!
In this three-part webinar series, we will explore several areas critical to LNP vaccine and gene therapy development.
Topics include an overview of LNP structure and formulation, the common and advanced analytics used to characterize LNPs, and what LNP physicochemical properties are measured.
We will discuss in-depth the light scattering analytics used to measure LNP size, polydispersity, charge, and particle concentration.
Key considerations for LNP development, including structure and formulation. We explore analytics, physicochemical properties and quality attributes. Register now >>
We highlight the need to understand and control LNP stability from formulation to manufacturing, utilizing DLS and NTA. Register now >>
We explore the importance of LNP charge and zeta potential, including ELS theory and best practices for zeta potential methods. Register now >>
In this three-part webinar series, we will explore nanoparticles and NTA.
Biological nanoparticles are being explored for a range of applications within the life science industry, such as diagnostics and gene delivery. The ability to characterize these particles is a crucial part of understanding their behavior and effectiveness. In this three-part webinar series, we will explore several areas in the characterization of exosomes and other biologically-sourced nanoparticles, including an overview of techniques commonly used to characterize biologically sourced nanoparticles, with a special focus on nanoparticle tracking analysis (NTA). In addition, we will discuss, in-depth, the best practices to obtain quality NTA data, and how to optimize fluorescence NTA measurements.
Find out more about each webinar in this series below:
Biologically-sourced nanoparticles are promising for diagnostics, drug delivery and gene therapy vectors. Characterizing nanoparticles is crucial to unlocking potential. Register now >>
Fluorescence-NTA measures particle size, distribution and fluorescently labeled particles, unlocking potential for diagnostics and therapeutics. Register now >>
Nanosight instruments use NTA for high-res particle size and concentration, widely used to characterize nanoparticles. Register now >>
Our Lab to Clinic Pharmaceutical Development Series will explore development techniques for a variety of pharmaceutical requirements.
Save the date for our events! We will update this page with registration links soon.
Lab to Clinic - Pharmaceutical Development Series | Date |
---|---|
Orthogonal technologies for candidate selection | June 27 |
Rapid screening for binding kinetics | July 11 |
Screening and controlling API polymorphs | July 25 |
Developing nasal sprays, aerosols and inhalers for drug delivery | August 8 |
Our Method Validation Series will explore development and validation of methods in regulated environments, as well as building methods for our most popular instruments.
Save the date for our events! We will update this page with registration links soon.
Method Validation Series | Date |
---|---|
Challenges Associated with validation in regulatory environment | November 14 |
Zetasizer method validation | November 26 |
Mastersizer 3000 method validation | December 5 |
Empyrean / Aeris method validation | December 12 |